Video capsules

Urothelial Carcinoma: EV-301 Update from ASCO 2022

Dr. Nimira Alimohamed discusses updates on the treatment of urothelial carcinoma, focusing on data from the EV-301 trial presented at the ASCO 2022 virtual meeting.

9 minutes

Hodgkin Lymphoma: ECHELON-1 Update from ASCO 2022 (French)

Dr. Jean-Francois Larouche discusses updates on the treatment of cHL, focusing on data from the ECHELON-1 trial presented at the ASCO 2022 virtual meeting. (In French)


10 minutes

Hodgkin Lymphoma: ECHELON-1 Update from ASCO 2022

Dr. John Kuruvilla discusses updates on the treatment of cHL, focusing on data from the ECHELON-1 trial presented at the ASCO 2022 virtual meeting.

18 minutes

Highlights from ASCO/EHA 2021: Updates in CLL

Dr. Carolyn Owen discusses updates on the treatment of CLL from the ASCO/EHA 2021 virtual meetings.

24 minutes

ASCO/EHA 2021: traitement de la LLC

Le Dr Stephane Doucet discute des principales études sur la LLC qui ont été présentées au congrès virtuel de l’ASCO et EHA de 2021.

40 minutes

Highlights from ASH 2021: Updates in CLL

Dr. Carolyn Owen discusses updates on the treatment of CLL from the ASH 2021 meeting.

22 minutes

ASH 2021: traitement de la LLC

Dr. Michel Pavic, Onco-hématologue a l’Estrie-CHUS, discute des principales études sur la LLC qui ont été présentées au congrès virtuel de l’ASH de 2021.


27 minutes

CGP Report: Recommendations for Funders

Dr. Sandeep Sehdev discusses recommendations for funding comprehensive genomic profiling for payers in Canada. The full CGP report is available at: https://www.impactmedicom.com/publications/reports. Funding for the CGP report was provided by AstraZeneca, Roche, and Illumina.

35 minutes

ASH 2020: Updates on CLL

Dr. Carolyn Owen discusses updates on the treatment of CLL from the ASH 2020 virtual meeting.

18 minutes

ASH 2020: traitement de la LLC

La Dre Silvy Lachance discute des principales études sur la LLC qui ont été présentées au congrès virtuel de l’ASH de 2020.


36 minutes

BTK Inhibitors for the Frontline Treatment of CLL

Dr. Laurie Sehn discusses the management of BTK-related toxicities, based on a recently published paper in Current Oncology by Dr. Laurie Sehn, Dr. Andrew Aw & Dr. Sue Robinson.

28 minutes

Les inhibiteurs de la BTK pour le traitement de première intention de la LLC Présentation

La Dre Inès Chamakhi discute de la prise en charge des toxicités liées aux inhibiteurs de la BTK d’après un article récemment publié dans la revue Current Oncology par la Dre Laurie Sehn , le Dr Andrew Aw et la Dre Sue Robinson.

20 minutes

Treatment of CLL during COVID-19

Dr. Laurie Sehn discusses the treatment of CLL during the coronavirus pandemic, based on a recently published paper by Dr. Laurie Sehn, Dr. Philip Kuruvilla, and Dr. Julie Stakiw. The full paper can be found here: https://www.current-oncology.com/inde....


20 minutes

Prise en charge de la LLC au Canada pendant la pandémie de COVID-19

Dr Michel Pavic discute du traitement de la LLC à l’ère de la pandémie de Covid 19, d’après les résultats d’un article publié récemment dans la revue Current Oncology (Dre Laurie Sehn, Dr Philip Kuruvilla et Dre Julie Stakiw).

20 minutes

ASCO 2020: CLL Updates

Dr. Mona Shafey presents key updates on the treatment of chronic lymphocytic leukemia from the ASCO 2020 virtual Meeting.

32 minutes

ENGLISH: NGS Guidelines

Dr. Stephen Yip, Director of the Cancer Genetics & Genomics Lab at BC Cancer in Vancouver, British Columbia, presents a summary of the first Canadian guidelines on Next Generation Sequencing (NGS). The published guidelines can be found in the April issue of Current Oncology.

2 hours

FRENCH: NGS Guidelines

Dr. Patrice Desmeules, Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval, Québec, QC presents a summary of the recently published Canadian guidelines on next generation sequencing (NGS).

1 hr 40 minutes

ASH 2019: CLL Updates

Dr. Versha Banerji Discusses Practice-Changing Studies in Treatment-Naive CLL.

23 minutes

**Funding provided by AstraZeneca, Janssen, Seagen Canada

Tel. 416-434-8923

Email. info@impactmedicom.com